Aggressive and indolent non-Hodgkin's lymphoma: Response assessment by integrated international workshop criteria

被引:32
作者
Brepoels, Lieselot
Stroobants, Sigrid
De Wever, Walter
Spaepen, Karoline
Vandenberghe, Peter
Thomas, Jose
Uyttebroeck, Anne
Mortelmans, Luc
De Wolf-Peeters, Christiane
Verhoef, Gregor
机构
[1] Univ Hosp Gasthuisberg, Dept Nucl Med, B-3000 Louvain, Belgium
[2] Univ Hosp Gasthuisberg, Dept Radiol, B-3000 Louvain, Belgium
[3] Univ Hosp Gasthuisberg, Ctr Human Genet, B-3000 Louvain, Belgium
[4] Univ Hosp Gasthuisberg, Dept Clin Oncol, B-3000 Louvain, Belgium
[5] Univ Hosp Gasthuisberg, Dept Pediat Hemato Oncol, B-3000 Louvain, Belgium
[6] Univ Hosp Gasthuisberg, Dept Pathol, B-3000 Louvain, Belgium
[7] Univ Hosp Gasthuisberg, Dept Hematol, B-3000 Louvain, Belgium
[8] Catholic Univ Louvain, B-3000 Louvain, Belgium
关键词
non-Hodgkin's lymphoma; response assessment; CT; PET;
D O I
10.1080/10428190701474365
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Until recently, response assessment in patients with lymphoma was primarily performed by computed tomography (CT). Based on CT, International Workshop Criteria (IWC) were developed and widely used. Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) is a more sensitive and specific imaging technique for the detection of residual disease in lymphoma, and Revised Integrated International Workshop Criteria (IWC+PET) were recently proposed by the members of the International Harmonization Project (IHP), which combine both imaging techniques. We determined whether these new IWC+PET-criteria, can more accurately predict outcome compared to IWC-criteria in aggressive and indolent non-Hodgkin's lymphoma (NHL), and therefore correlated IWC and IWC+PET response with time-to-next-treatment (TNT) in 69 patients with NHL. We demonstrated that IWC+PET-guidelines are highly recommended over IWC-uidelines for patients with potentially-curable and routinely FDG-avid lymphoma. In contrast, no additional value of IWC+PET was demonstrated in a small group of patients with incurable histological subtypes.
引用
收藏
页码:1522 / 1530
页数:9
相关论文
共 19 条
  • [1] Staging non-Hodgkin lymphoma
    Armitage, JO
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2005, 55 (06) : 368 - 376
  • [2] Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol
    Atra, A
    Imeson, JD
    Hobson, R
    Gerrard, M
    Hann, IM
    Eden, OB
    Carter, RL
    Pinkerton, CR
    [J]. BRITISH JOURNAL OF CANCER, 2000, 82 (08) : 1396 - 1402
  • [3] Barosi G, 2005, HAEMATOLOGICA, V90, P1236
  • [4] Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas
    Cheson, BD
    Horning, SJ
    Coiffier, B
    Shipp, MA
    Fisher, RI
    Connors, JM
    Lister, TA
    Vose, J
    Grillo-López, A
    Hagenbeek, A
    Cabanillas, F
    Klippensten, D
    Hiddemann, W
    Castellino, R
    Harris, NL
    Armitage, JO
    Carter, W
    Hoppe, R
    Canellos, GP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) : 1244 - 1253
  • [5] Revised response criteria for malignant lymphoma
    Cheson, Bruce D.
    Pfistner, Beate
    Juweid, Malik E.
    Gascoyne, Randy D.
    Specht, Lena
    Horning, Sandra J.
    Coiffier, Bertrand
    Fisher, Richard I.
    Hagenbeek, Anton
    Zucca, Emanuele
    Rosen, Steven T.
    Stroobants, Sigrid
    Lister, T. Andrew
    Hoppe, Richard T.
    Dreyling, Martin
    Tobinai, Kensei
    Vose, Julie M.
    Connors, Joseph M.
    Federico, Massimo
    Diehl, Volker
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) : 579 - 586
  • [6] How to interpret the radiological abnormalities that persist after treatment in non-Hodgkin's lymphoma patients?
    Coiffier, B
    [J]. ANNALS OF ONCOLOGY, 1999, 10 (10) : 1141 - 1143
  • [7] FDG-PET/CT in re-staging of patients with lymphoma
    Freudenberg, LS
    Antoch, G
    Schütt, P
    Beyer, T
    Jentzen, W
    Müller, SP
    Görges, R
    Nowrousian, MR
    Bockisch, A
    Debatin, JF
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (03) : 325 - 329
  • [8] HARRIS NL, 1994, BLOOD, V84, P1361
  • [9] Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging
    Jerusalem, G
    Beguin, Y
    Fassotte, MF
    Najjar, F
    Paulus, P
    Rigo, P
    Fillet, G
    [J]. BLOOD, 1999, 94 (02) : 429 - 433
  • [10] Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL)
    Jerusalem, G
    Beguin, Y
    Najjar, F
    Hustinx, R
    Fassotte, MF
    Rigo, P
    Fillet, G
    [J]. ANNALS OF ONCOLOGY, 2001, 12 (06) : 825 - 830